Core Viewpoint - The company has developed DT678 tablets, a globally innovative drug for anti-platelet aggregation, which is currently in Phase II clinical trials and shows superior efficacy compared to Clopidogrel with fewer side effects [1][3]. Group 1 - DT678 tablets are a co-development between the company and DT Company, which is partially owned by the University of Michigan, with the company holding a 30% stake in DT Company [1][3]. - The company possesses exclusive rights for the development and use of the patented compound in China [1][3]. - Preliminary results from Phase I trials indicate that DT678 has over 20 times the efficacy of Clopidogrel, with advantages such as rapid onset, fewer side effects, and greater stability [3].

Summary of Conference Call Notes Industry Overview - The conference call discusses the upcoming **11th National Drug Centralized Procurement (国采)**, expected to start in **July or August 2025**. The 10th round had extreme results due to a long time span and rule adjustments, leading to potential product registration backlog issues in the 11th round, with intensified competition and possible rule changes to avoid excessive low pricing [1][4][2]. Key Points and Arguments - **11th Batch Procurement Timing**: The 11th batch is likely to be delayed until the second half of the year due to the need for medical institutions to prepare reporting volumes, with only one round expected this year [2]. - **Biological Drug Procurement**: The biological drug procurement led by Anhui is set for execution by the end of **2025**, based on insulin procurement rules, focusing on moderate price reductions and a larger number of selected products [1][5][6]. - **Quality Control Measures**: The National Medical Products Administration (药监局) is responsible for quality control of selected products, while the National Healthcare Security Administration (医保局) has introduced new rules requiring companies to have market volume before gaining market share, ensuring fair competition [7][3]. - **Impact of New Rules on Original Drug Companies**: The new procurement rules favor original drug companies by allowing them to retain some market share even if not selected, and providing hospitals with more autonomy in choosing products [12][3]. - **Price Discrimination Issues**: The centralized procurement has provided a price benchmark, but there have been instances of price discrimination across provinces, leading to a downward spiral in drug prices and potential shortages [18][19]. - **Market Dynamics for Generic Drugs**: The procurement process has increased the penetration of competitive products in grassroots hospitals, while high-priced drugs have significant market expansion potential [11][21]. Additional Important Content - **Alliance Procurement Framework**: The shift to an alliance procurement framework has led to varied approaches among provinces, with some like Hebei being aggressive in pricing, while others like Guangdong and Xinjiang adopt a more balanced approach [8][9]. - **Future Alliance Plans**: Major alliances for procurement include those led by Sichuan, Xinjiang, Guangdong, and Tianjin, with Shanghai and Jiangsu considering joining new projects [9]. - **Impact on Marketing Strategies**: Original drug companies are adjusting their marketing strategies, increasing collaboration with e-commerce channels to enhance drug accessibility and sales [22][24]. - **Medicare Payment Standards**: The establishment of Medicare payment standards is expected to significantly impact drug prices and market dynamics, potentially leading to a unified pricing structure across different regions [13][20]. - **Challenges for Innovative Drugs**: The procurement policies may limit the development of innovative drugs due to low pricing, which could discourage research and development efforts in the pharmaceutical industry [25][26]. This summary encapsulates the critical insights and implications from the conference call regarding the upcoming drug procurement policies and their potential impact on the pharmaceutical industry.

或受此影响，3月26日开盘，恒瑞医药股价小幅上涨，随后稍有回落，截至发稿涨超3%，总市值为2953 亿元。 恒瑞医药方面表示，借助默沙东在心血管领域的领先地位（其抗血小板药物氯吡格雷年销售额超50亿美 元）及覆盖120国的销售网络，可加速实现创新价值转化，同时还能规避海外高昂的研发投入和法规风 险。 实际上，恒瑞医药一直在通过海外授权，来完成其出海战略。粗略统计，恒瑞医药已有13项创新药实现 海外授权。值得一提的是，2024年5月，恒瑞医药将具有自主知识产权的GLP-1类创新药HRS-7535、 HRS9531、HRS-4729许可给美国Kailera公司。彼时，首付款加里程碑付款累计高达约60亿美元，并且 还取得美国Kailera公司19.9%的股权。 加速出海的背后，是恒瑞医药在研发方面的大力投入。2024年前三季度业绩报告显示，其研发费用达 45.49亿元，同比增长22.1%。目前，恒瑞医药已在全球布局 14 个研发中心，组建了超 5500 人的全球研 发团队；在中国获批上市的有19款新分子实体药物（1类创新药）和4款其他创新药（2类新药）。 加速出海，恒瑞医药与默沙东签下19.7亿美元大单 3月25日 ...